Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

Ins ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

SINTEF has also signed a licence agreement with a pharmaceutical company. We're very confident that this approach may offer us a new cure for lung cancer." It was in many ways something of a ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...